Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to “Hold” at Zacks Research

Theravance Biopharma (NASDAQ:TBPH) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities research analysts have also issued reports on TBPH. B. Riley Financial lifted their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. TD Cowen lifted their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd. BTIG Research reissued a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. Finally, Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Theravance Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Trading Up 1.2%

Shares of TBPH stock opened at $16.49 on Monday. Theravance Biopharma has a 1 year low of $10.42 and a 1 year high of $21.03. The firm’s fifty day moving average price is $16.42 and its two-hundred day moving average price is $17.50. The firm has a market capitalization of $850.06 million, a P/E ratio of 7.50 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million during the quarter. As a group, equities research analysts forecast that Theravance Biopharma will post 1.58 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 7.65% of the company’s stock.

Institutional Trading of Theravance Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the period. CIBC Private Wealth Group LLC boosted its holdings in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.